Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc reported a 3.7% year-over-year increase in total net revenue, reaching $69.4 million, driven by higher volumes of its flagship product, Jeuveau, and the successful launch of its Evolysse dermal filler line. The company has raised its 2025 top-line guidance contributions from Evolysse to 10-12% of overall revenue, translating to approximately $33 million, indicating strong initial demand. Furthermore, the broader market for aesthetic treatments is anticipated to grow significantly, particularly among younger consumers, positioning Jeuveau favorably for future market share gains.

Evolus Inc's adjusted gross margin declined to 66.5% from 71.5% year-over-year, primarily influenced by a higher proportion of international sales and introductory pricing strategies designed to boost product adoption. The company significantly lowered its 2025 net revenue guidance to a range of $295-$305 million, a stark reduction from the previous forecast of $345-$355 million, indicating a marked decrease in expected growth rates from 30%-33% to 11%-15%. Additionally, Jeuveau experienced a notable sales decline, with second-quarter revenues of $59.0 million reflecting a 13% quarter-over-quarter and 11% year-over-year decrease, attributed to declining consumer sentiment and overall softness in the U.S. aesthetic market.